The INT Difference

What differentiates INT from other companies is our focus on the underlying mechanisms responsible for Tau dysregulation and dementias.  We are developing disease-modifying biotherapeutics to prevent, delay, or ameliorate the cognitive deficits resulting from tauopathies, such as in AD, FTD, or CTE, using passive immunization.  This will at least delay onset or mitigate these dementias.

In addition, INT intends to target an orphan indication, such as PSP or CBD, with its anti-Tau candidates to gain prospective “fast-track” designation through the FDA with smaller and more cost effective clinical trials.